■预后营养指数(PNI)已成为评估患者营养状况和免疫能力的重要预测工具。它广泛用于各种癌症患者的预后评估。然而,在接受免疫检查点抑制剂(ICIs)治疗的胃癌或胃食管交界处癌(GC/GEJC)患者中,预后营养指数(PNI)的预后相关性尚不清楚.这项荟萃分析旨在确定PNI在该特定患者队列中的预后影响。
■我们进行了彻底的文献检索,涵盖诸如PubMed之类的著名数据库,Embase,WebofScience,SpringerLink,还有Cochrane图书馆.搜索从这些数据库开始到2023年12月5日。采用95%置信区间和危险比(HR),该研究系统地评估了PNI与关键预后指标之间的关系,包括客观缓解率(ORR),疾病控制率(DCR),接受ICI治疗的GC/GEJC患者的总生存期(OS)和无进展生存期(PFS).
■选择了包含813名合格患者的8项研究。有7项研究一致证明高预后营养指数(PNI)组的总生存率(OS)优于低PNI组(HR0.58,95%CI:0.47-0.71,P<0.001)。此外,来自6项研究的结果指出,低PNI与较差的无进展生存期(PFS)之间存在显着相关性(HR0.58,95%CI:0.47-0.71,P<0.001)。进行亚组分析以验证结果的稳健性。此外,我们对三项研究PNI与客观缓解率/疾病控制率(ORR/DCR)之间的相关性进行了荟萃分析,发现高PNI组的ORR/DCR显著优于高PNI组(ORR:RR:1.24,P=0.002;DCR:RR:1.43,P=0.008).
■这项荟萃分析表明,接受ICI治疗的GC/GEJC患者的低PNI与OS和PFS恶化显著相关。因此,PNI可以作为接受ICI的GC患者治疗后预后指标。需要进一步的前瞻性研究来评估这些发现的可靠性。
■https://inplasy.com/,标识符INPLASY202450133。
UNASSIGNED: The Prognostic Nutritional Index (PNI) has become an important predictive tool for assessing patients\' nutritional status and immune competence. It is widely used in prognostic evaluations for various cancer patients. However, the prognostic relevance of the Prognostic Nutritional Index (PNI) in gastric or gastro-esophageal junction cancer patients (GC/GEJC) undergoing immune checkpoint inhibitors (ICIs) treatment remains unclear. This meta-analysis aimed to determine the prognostic impact of PNI in this specific patient cohort.
UNASSIGNED: We conducted a thorough literature search, covering prominent databases such as PubMed, Embase, Web of Science, SpringerLink, and the Cochrane Library. The search spanned from the inception of these databases up to December 5, 2023. Employing the 95% confidence interval and Hazard Ratio (HR), the study systematically evaluated the relationship between PNI and key prognostic indicators, including the objective remission rate (ORR), disease control rate (DCR), overall survival (OS) and progression-free survival (PFS) in GC/GEJC patients undergoing ICI treatment.
UNASSIGNED: Eight studies comprising 813 eligible patients were selected. With 7 studies consistently demonstrating superior Overall Survival (OS) in the high-Prognostic Nutritional Index (PNI) group compared to their low-PNI counterparts (HR 0.58, 95% CI: 0.47-0.71, P<0.001). Furthermore, the results derived from 6 studies pointed out that the significant correlation between he low-PNI and poorer progression-free survival (PFS) (HR 0.58, 95% CI: 0.47-0.71, P<0.001). Subgroup analyses were performed to validate the robustness of the results. In addition, we conducted a meta-analysis of three studies examining the correlation between PNI and objective response rate/disease control rate (ORR/DCR) and found that the ORR/DCR was significantly superior in the high PNI group (ORR: RR: 1.24, P=0.002; DCR: RR: 1.43, P=0.008).
UNASSIGNED: This meta-analysis indicates that the low-PNI in GC/GEJC patients undergoing ICI treatment is significantly linked to worse OS and PFS. Therefore, PNI can serve as a prognostic indicator of post-treatment outcomes in patients with GC receiving ICIs. Further prospective studies are required to assess the reliability of these findings.
UNASSIGNED: https://inplasy.com/, identifier INPLASY202450133.